COMBINACION FARMACÉUTICA PARA EL TRATAMIENTO Y/O QUIMIOSENSIBILIZACION DE TUMORES REFRACTARIOS A DROGAS ANTICANCERIGENAS

• Main Authors: CASTELLANOS SERRA, LILA ROSA, BESADA PEREZ, VLADIMIR, PEREA RODRIGUEZ, SILVIO ERNESTO, RAMOS GOMEZ, YASSEL, GIL VALDES, JEOVANIS, RODRIGUEZ ULLOA, ARIELIS, GONZALEZ LOPEZ, LUIS JAVIER, SANCHEZ PUENTE, ANIEL, BENTANCOURT NUNEZ, LAZARO HIRAM, GOMEZ, DANIEL EDUARDO, ACEVEDO CASTRO, BORIS ERNESRO, FERNANDEZ DE COSSIO DORTA DUQUE, ALONSO, DANIEL FERNANDO, PERERA NEGRIN, YASSER
• Format: Patent
• Language: Spanish
• Published: 31.01.2008
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Combinacion farmacéutica que incluye un inhibidor de la fosforilacion de la caseína Kinasa 2 (denominado P15) y los citostáticos usados en la quimioterapia del cáncer los cuales son administrados simultáneos, separados o secuencialmente. La sinergia entre el péptido P15 y los compuestos químicos anticancerígenos, hace que la combinacion descrita tenga una toxicidad mucho menor que para los citostáticos anticancerígenos lo cual representa una ventaja crucial para su uso en el tratamiento del cáncer. Adicionalmente, la combinacion administrada de manera secuencial produce la quimiosensibilizacion de tumores refractarios a los citostáticos mencionados mediante el pretratamiento con el péptido P15. This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.